The future of oncology | KPMG | CN
close
Share with your friends

The future of oncology: A focused approach to winning in 2030

The future of oncology

An analysis of how current business models can be adapted to mitigate the effects of a changing oncology paradigm

1000

Related content

saline drip

Oncology treatments used to promise some of the highest returns for pharmaceutical manufacturers. However, R&D costs, shorter product life cycles, fragmented patient markets and pressure on healthcare budgets are changing the industry’s status quo.

The age of the ‘one-size-fits-all’ oncology therapy is ending, and with it the blockbuster model that has for so long driven shareholder value. The future of oncology: A focused approach to winning in 2030 analyses how current business models can be adapted to mitigate the effects of a changing oncology paradigm.

Connect with us